Head-to-head evidence
ASC30 vs dapiglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
dapiglutide
Developed by Zealand Pharma
NCT06758583 · Phase 1 · completed
Both groups received active dapiglutide at different concentrations with no placebo or blinding, and the study measured only drug levels in the blood rather than a clinical effect. No results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · dapiglutide's landscape